What is the catalog number for Exendin-4?

The catalog number for Exendin-4 is HY-13443.

What sizes are available for Exendin-4?

Exendin-4 is available in the following size(s): 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does Exendin-4 come in?

Exendin-4 is available in 6 different pack sizes.

Is Exendin-4 in stock?

Exendin-4 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Exendin-4?

Exendin-4 is manufactured by QuantiMol.

What is the estimated delivery time for Exendin-4?

Estimated delivery time for Exendin-4 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Exendin-4?

The safety data sheet for Exendin-4 is available here: http://file.medchemexpress.com/batch_PDF/HY-13443/Exendin-4-SDS-MedChemExpress.pdf.

Can I return this product if I ordered the wrong one?

As a consumer, you have a 14-day right of withdrawal from receipt under EU consumer protection law, submitted via our withdrawal/cancellation request form. Note this applies to unused, undamaged products, and doesn’t override the expiry/storage conditions on performance-based claims.

Is this product tested for endotoxin levels?

Endotoxin testing status is noted on the datasheet where applicable, particularly for recombinant proteins intended for cell-based or functional assays. If this isn’t listed and you need confirmation, contact support with the catalogue number.

Can I request additional validation data, such as western blot images, for this product?

Additional data may be available on request. Contact our technical support team with the catalogue number and we’ll check what supporting documentation the supplier can provide.

Exendin-4

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC50 of 3.22 nM.

Product Specifications

CAS Number

141758-74-9

Product Name Alternative

Exenatide

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

GCGR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Exendin-4.html

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 33.33 mg/mL (ultrasonic)

Smiles

O=C(NCC(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(NCC(NCC(N5[C@@H](CCC5)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N6[C@@H](CCC6)C(N7[C@@H](CCC7)C(N8[C@@H](CCC8)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC9=CNC=N9)N

Molecular Formula

C184H282N50O60S

Molecular Weight

4186.57

Precautions

H302, H315, H319, H335

References & Citations

[1]Doyle ME, et al. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept. 2003 Jul 15;114 (2-3) :153-8.|[2]Wei R, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016 Jun 1;310 (11) :E947-57.|[3]Fidan-YaylalI G, et al. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. Tumour Biol. 2016 Feb;37 (2) :2647-53.|[4]Ding X, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/obmice. Hepatology. 2006 Jan;43 (1) :173-81.|[5]Nachnani JS, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010 Jan;53 (1) :153-9.|[6]Selley E, et al. Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. Cardiovasc Diabetol. 2014 Apr 2;13:69.